Grade II and III Oligodendroglioma and Astrocytoma
In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors. Standard of care for grade II and III glioma consists of resection. For patients with tumors that require postoperative treatment, radiotherapy and chemotherapy are recommended. Trials in newly diagnosed grade II and III glioma have shown survival benefit of the addition of chemotherapy to radiotherapy compared with initial treatment with radiotherapy alone; both temozolomide and PCV have been shown to improve survival.
|Keywords||1p/19q codeletion, Anaplastic, Astrocytoma, Bevacizumab, IDH, Oligodendroglioma, PCV, Temozolomide|
|Persistent URL||dx.doi.org/10.1016/j.ncl.2018.04.005, hdl.handle.net/1765/114109|
van den Bent, M.J, & Chang, S.M. (2018). Grade II and III Oligodendroglioma and Astrocytoma. Neurologic Clinics (Vol. 36, pp. 467–484). doi:10.1016/j.ncl.2018.04.005